The majority of shared melanoma antigens identified thus far can be divided into two groups; 1) melanocyte differentiation proteins (MDP) and 2) cancer-testis antigens (CTA). Generally, both types of proteins are encoded by non-mutated genes, which lack tumor-specific mutations. Therefore, epitopes derived from these molecules could be useful in a vaccine for a large population of melanoma patients. Interestingly, MDP and CTA are differentially expressed in various stages of melanoma. Generally, the expression of MDA decreases in more metastatic lesions, whereas the expression of CTA increases in metastatic lesions. Thus, metastatic tumors contain a heterogeneous population of cells with respect to protein expression, Based on the emergence of metastases that have lost expression of target antigens vaccines that incorporate single melanoma derived epitopes may be inadequate in generating a complete immune response against the tumor. Ideally, a polyvalent vaccine that incorporates epitopes derived from both groups of antigens should compensate for the differential display of melanoma-associated antigens. Preliminary data from an ongoing vaccine trial at the University of Virginia (UVA-Me139) support the safety and immunogenicity of a vaccine strategy incorporating 12 melanoma peptides. This 12-peptide preparation will be used in the currently proposed study. Granulocyte-macrophage colony stimulating factor (GM-CSF) has been included in our vaccine regimens as a local cytokine adjuvant. The rationale for inclusion of GM-CSF is based on substantial murine and human data, but other studies with Montanide ISA-51 adjuvant alone have been demonstrated immunogenicity in the absence of GMCSF. In the present study, we propose to test the hypothesis that the GM-CSF included in this regimen contributes to a heightened cellular immune response compared to vaccination in Montanide ISA-51 adjuvant alone. A second question being addressed in this study is the immunologic consequences of vaccination in more than one injection site. In the following study, we propose a 2-by-2 design to address both questions. The primary goals are to estimate: (1) whether GM-CSF administered locally changes the immunogenicity of vaccination with multiple synthetic melanoma peptides in an emulsion with incomplete Freund's adjuvant, (2) whether vaccination at two extremity sites induces different immunogneicty than vaccination at a single site. Secondary goals are to obtain preliminary data on (3) whether booster vaccination every three months may maintain immune responses to a peptide vaccine, and (4) whether celluar immune responses to a 12-peptide vaccine may correlate with clinical outcome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA103528-02
Application #
6786076
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Xie, Heng
Project Start
2003-08-05
Project End
2005-07-31
Budget Start
2004-08-02
Budget End
2005-07-31
Support Year
2
Fiscal Year
2004
Total Cost
$338,200
Indirect Cost
Name
University of Virginia
Department
Surgery
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Hu, Yinin; Kim, Helen; Blackwell, Christopher M et al. (2015) Long-term outcomes of helper peptide vaccination for metastatic melanoma. Ann Surg 262:456-64; discussion 462-4
Ramirez, Adriana G; Wages, Nolan A; Hu, Yinin et al. (2015) Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience. Cancer Immunol Immunother 64:1531-9
Hu, Yinin; Petroni, Gina R; Olson, Walter C et al. (2014) Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother 63:779-86
Hu, Yinin; Smolkin, Mark E; White, Emily J et al. (2014) Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma. Ann Surg Oncol 21:3978-84
Clancy-Thompson, Eleanor; King, Laura K; Nunnley, Lenora D et al. (2013) Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunol Res 1:332-9
Olson, Walter C; Smolkin, Mark E; Farris, Erin M et al. (2011) Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. J Transl Med 9:26
Slingluff, Craig L; Petroni, Gina R; Smolkin, Mark E et al. (2010) Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother 33:630-8
Chianese-Bullock, Kimberly A; Lewis, Sarah T; Sherman, Nicholas E et al. (2009) Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine 27:1764-70
Slingluff Jr, Craig L; Petroni, Gina R; Olson, Walter C et al. (2009) Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036-44